Imaging for the Pretreatment Staging of Small Cell Lung Cancer

Project Summary Title and Description

Title
Imaging for the Pretreatment Staging of Small Cell Lung Cancer
Description
Systematic Review for AHRQ EPC Program
Attribution
N/A
Authors of Report
N/A
Methodology description
Using EPC methods, we systematically review data on the pretreatment staging of small cell lung cancer
PROSPERO
CRD42014015429
DOI
10.7301/Z0862DC8
Notes
The URL of the AHRQ report is not yet available as of 7-20-15 The PMID of the published report is not yet available as of 7-20-15 Data entered retrospectively
Funding Source
AHRQ

Key Questions

1. Key Question 1: What are the test concordance and comparative accuracy of imaging tests (MDCT, PET/CT, MRI, PET/MRI, EBUS, EUS, bone scintigraphy) for the pretreatment staging of SCLC? a. Test concordance b. Sensitivity c. Specificity d. Positive predictive value e. Negative predictive value f. Positive likelihood ratio g. Negative likelihood ratio
2. Key Question 2: When used for the pretreatment staging of SCLC, what is the comparative effectiveness of imaging tests (MDCT, PET/CT, MRI, PET/MRI, EBUS, EUS, bone scintigraphy) on later outcomes? a. Choice of treatment (e.g., surgery, chemotherapy, radiation) b. Timeliness of treatment c. Tumor response d. Harms due to overtreatment or undertreatment e. Survival f. Quality of life
3. Key Question 3. To what extent are the following factors associated with the comparative accuracy or effectiveness of imaging tests (MDCT, PET/CT, MRI, PET/MRI, EBUS, EUS, bone scintigraphy) when used for the pretreatment staging of SCLC? a. Comorbidities b. Body habitus c. Tumor characteristics

Associated Extraction Forms

Downloadable Data Content

Files
  • XLSX Project Data